Compare Crispr Therapeutics AG (CRSP) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs NRG Energy Inc — how do they compare? Crispr Therapeutics AG trades at $53.52 (market cap $4.88B), while NRG Energy Inc trades at $106.87 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 4.6× Crispr Therapeutics AG's market cap, and NRG Energy Inc pays a 1.79% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and NRG Energy Inc for 62 Days on average.
| CRSP | NRG | |
|---|---|---|
Market Cap | $4.88B | $22.35B |
Volume | 2,861,747 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $74.92 | $184.03 |
52-Week Low | $44.34 | $95.23 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
NRG Energy (NRG) trades at $108.61, up 4.84% today, with a bullish technical signal and strong analyst consensus. Recent earnings showed a Q2 2026 miss but the company is executing a growth strategy including a 1.2 GW Texas data-center power project. Financials indicate solid revenue of $30.71B in 2025, though net margins are thin at 2.56%, and cash flow trends are volatile with a projected net outflow in 2026.
The outlook is positive given high analyst buy ratings and a $202.90 price target, but risks include execution on large capital projects, rising debt levels, and competitive pressures. Earnings growth from new assets and customer relationships remains the key catalyst for upside, though the stock faces near-term volatility from recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
